Companies Carrick Therapeutics

Fighting aggressive cancers


Carrick Therapeutics is developing a range of treatments that aim to slow down or impede the progress of the most aggressive forms of cancer.

Its therapies have attracted investment and collaborations with pharmaceutical industry leaders, with its lead drug, samuraciclib, in active clinical development for the treatment of advanced breast cancer.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More